within Pharmacolibrary.Drugs.ATC.R;

model R05DB29
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.78,
    Cl             = 8.833333333333333e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.111,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.020000000000001,            
    Vdp             = 0.0692,
    k12             = 38.9,
    k21             = 38.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R05DB29</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gefapixant is a selective P2X3 receptor antagonist used for the treatment of refractory or unexplained chronic cough in adults. It is an orally administered small molecule. Gefapixant received approval for this indication in several regions including the United States and Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers. Parameter values are population estimates following single oral dosing.</p><h4>References</h4><ol><li><p>Nussbaum, JC, Hussain, A, Min, KC, Marbury, TC, Lasseter, K, Stoch, SA, &amp; Iwamoto, M (2022). Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist. <i>Journal of clinical pharmacology</i> 62(11) 1435–1444. DOI:<a href=\"https://doi.org/10.1002/jcph.2094\">10.1002/jcph.2094</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35656754/\">https://pubmed.ncbi.nlm.nih.gov/35656754</a></p></li><li><p>Nussbaum, JC, Hussain, A, Ma, B, Min, KC, Evers, R, Li, Y, Garrett, G, Stoch, SA, &amp; Iwamoto, M (2022). Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist. <i>Clinical pharmacology in drug development</i> 11(1) 123–128. DOI:<a href=\"https://doi.org/10.1002/cpdd.988\">10.1002/cpdd.988</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34145987/\">https://pubmed.ncbi.nlm.nih.gov/34145987</a></p></li><li><p>Nussbaum, JC, Hussain, A, Ma, B, Min, KC, Chen, Q, Tomek, C, Iwamoto, M, &amp; Stoch, SA (2022). Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. <i>Pharmacology research &amp; perspectives</i> 10(1) e00924–None. DOI:<a href=\"https://doi.org/10.1002/prp2.924\">10.1002/prp2.924</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35106949/\">https://pubmed.ncbi.nlm.nih.gov/35106949</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R05DB29;
